JVJeff N. Vanderbilt

Jeff N. Vanderbilt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeff N. Vanderbilt has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Anne Marie Gillespie

    Cardiovascular Research Institute, and Departments of 2Medicine and 3Pediatrics, University of California San Francisco, San Francisco, California

    1 shared publication
  • Daniel Ansaldi

    Cardiovascular Research Institute, and Departments of 2Medicine and 3Pediatrics, University of California San Francisco, San Francisco, California

    1 shared publication
  • Jess Edmondson

    Cardiovascular Research Institute, and Departments of 2Medicine and 3Pediatrics, University of California San Francisco, San Francisco, California

    1 shared publication
  • Leland G. Dobbs

    Cardiovascular Research Institute, and Departments of 2Medicine and 3Pediatrics, University of California San Francisco, San Francisco, California

    1 shared publication
  • Lennell Allen

    Cardiovascular Research Institute, and Departments of 2Medicine and 3Pediatrics, University of California San Francisco, San Francisco, California

    1 shared publication
  • Robert F. Gonzalez

    Cardiovascular Research Institute, and Departments of 2Medicine and 3Pediatrics, University of California San Francisco, San Francisco, California

    1 shared publication

Latest Publications

  • Directed Expression of Transgenes to Alveolar Type I Cells in the Mouse

    by Jeff N. Vanderbilt, Lennell Allen, Robert F. Gonzalez, Zachary Tigue, Jess Edmondson, Daniel Ansaldi, Anne Marie Gillespie, Leland G. Dobbs

    Podoplanin (RTI40, aggrus, T1α, hT1α-2, E11, PA2.26, RANDAM-2, gp36, gp38, gp40, OTS8) is a type I cell marker in rat lung. We show that a bacterial artificial chromosome vector containing the rat podoplanin gene (RTIbac) delivers a pattern of transgene expression in lung that is more restricted to mouse type I cells than that of the endogenous mouse podoplanin gene. RTIbac-transgenic mice expressed rat podoplanin in type I cells; type II cells, airways, and vascular endothelium were negative. A modified bacterial artificial chromosome containing internal ribosome entry site (IRES)-green fluorescent protein (GFP) sequences in the podoplanin 3′UTR expressed rat podoplanin and transgenic GFP in type I cells. RTIbac transgene expression was absent or reduced in pulmonary pleura, lymphatic endothelium, and putative lymphoid-associated stromal tissue, all of which contained abundant mouse podoplanin. Rat podoplanin mRNA levels in normal rat lung and RTIbac transgenic lung were 25-fold higher than in corresponding kidney and brain samples. On Western blots, transgenic rat and endogenous mouse podoplanin displayed very similar patterns of protein expression in various organs. Highest protein levels were observed in lung with 10- to 20-fold less in brain; there were low levels in thymus and kidney. Both GFP and rat podoplanin transgenes were expressed at extrapulmonary sites of endogenous mouse podoplanin gene expression, including choroid plexus, eye ciliary epithelium, and renal glomerulus. Because their pulmonary expression is more restricted than endogenous mouse podoplanin, RTIbac derivatives should be useful for mouse type I cell–specific transgene delivery.